Antihypertensive Effect of Aliskiren as Related to BMI in Young Female Egyptian with Metabolic Syndrome

Abstract

Abstract: Background: In view of the potential benefit of direct renin inhibition, this clinical research article was designed to assess blood pressure lowering to the target blood pressure in 100 young (18-25 years) Egyptian female patients with metabolic syndrome (MS) and with body mass index of 30 kg/m2 treated with aliskiren in multiple primary care units of female and child health all around Egypt. Methods: At an initial visit, physicians assessed baseline blood pressure (BP), (HR), risk factors, signs of end organ damage and prior antihypertensive medication. Patients were prescribed aliskiren 40 mg/kg/day orally. Efficacy and tolerability were measured by assessing blood pressure, and side effects at a further visit after two months. Blood pressure target was defined according to the Seventh Report of the Joint National Committee on Prevention, Detection, evaluation and Treatment of High Blood Pressure (JNC7) that recommends a BP treatment goal of <130/80 mmHg for patients MS with diabetes mellitus (DM). Results: Mean sitting systolic blood pressure/mean sitting diastolic blood pressure was lowered equally effectively (systolic/diastolic, p=1.0/0.8) in patients with metabolic syndrome (-22.0± 15.8/-10.9 ±9.6mmHg). Side effects were reported in 1% of all cases, none of them was life threatening. Conclusion: Aliskiren administration for 2 months at a dose of 40 mg/kg/day orally was effective in young Egyptian female who were hypertensive with MS.